OBI Pharma, Inc. (4174) Stock Price & Analysis
4174 Stock Chart & Stats
- Day’s Range
- TWD 43.00 - TWD 49.85
- 52-Week Range
- TWD 24.30 - TWD 66.80
- Previous Close
- TWD 46.95
- Volume
- N/A
- Average Volume (3M)
- 1.26M
- Market Cap
- TWD 6.38B
- Enterprise Value
- TWD 4.62B
- Total Cash (Recent Filing)
- TWD 496.96M
- Total Debt (Recent Filing)
- TWD 446.14M
- Price to Earnings (P/E)
- ―
- Beta
- 0.21
- Next Earnings
- Mar 15, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
4174 FAQ
What was OBI Pharma, Inc.’s price range in the past 12 months?
What is OBI Pharma, Inc.’s market cap?
When is OBI Pharma, Inc.’s upcoming earnings report date?
How were OBI Pharma, Inc.’s earnings last quarter?
Is OBI Pharma, Inc. overvalued?
Does OBI Pharma, Inc. pay dividends?
What is OBI Pharma, Inc.’s EPS estimate?
How many shares outstanding does OBI Pharma, Inc. have?
What happened to OBI Pharma, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of OBI Pharma, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
OBI Pharma, Inc.
OBI Pharma, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing cutting-edge therapies for critical medical needs, specifically in the field of cancer, with operations spanning Taiwan and international markets. The company's extensive product pipeline features numerous advanced treatment candidates. These include Adagloxad Simolenin (OBI-822), an active immunity drug for breast cancer designed to stimulate antibody production against the tumor carbohydrate antigen Globo H; OBI-833, an immunity-boosting anti-cancer agent targeting lung cancer; OBI-866 SSEA-4, another active immune-oncology medication; and OBI-888, a passive immunotherapy monoclonal antibody also developed to confront Globo H. Additionally, their portfolio contains OBI-999, an antibody-drug conjugate; OBI-3424, a small-molecule chemotherapy prodrug; OBI-858, a botulinum toxin; and other investigational drugs such as OBI-898 and OBI-998. Founded in 2002, the enterprise is headquartered in Taipei, Taiwan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Ya-Chi Chen
- Employees
- 260
- Website
- www.obipharma.com
- Address
- No. 3, Park Street, Taipei, TP, 115, TW
OBI Pharma, Inc. (4174) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 3 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 11 | 0 | 1 |

